Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2018

Open Access 01-12-2018 | Correction

Correction to: Identification of novel human RANK isoforms generated through alternative splicing. Implications in breast cancer cell survival and migration

Authors: Anastasios D. Papanastasiou, Chaido Sirinian, Haralabos P. Kalofonos

Published in: Breast Cancer Research | Issue 1/2018

Login to get access

Excerpt

After the publication of this article [1] we noticed that in Fig. 1, the gel images (1A and 1B lower panel) were incorrect. The corrected Fig. 1 is presented below. The correction does not affect in any way our results and conclusions. …
Literature
1.
Papanastasiou AD, Sirinian C, Kalofonos HP. Identification of novel human receptor activator of nuclear factor-kB isoforms generated through alternative splicing: implications in breast cancer cell survival and migration. Breast Cancer Res. 2012;14(4):R112.CrossRefPubMedPubMedCentral
Metadata
Title
Correction to: Identification of novel human RANK isoforms generated through alternative splicing. Implications in breast cancer cell survival and migration
Authors
Anastasios D. Papanastasiou
Chaido Sirinian
Haralabos P. Kalofonos
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2018
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/s13058-018-0985-z

Other articles of this Issue 1/2018

Breast Cancer Research 1/2018 Go to the issue

Retraction Note

Retraction Note: Nuclear factor of activated T cells 5 maintained by Hotair suppression of miR-568 upregulates S100 calcium binding protein A4 to promote breast cancer metastasis

Research article

Syndecan-1 induction in lung microenvironment supports the establishment of breast tumor metastases

Research article

Breast fibroadenomas are not associated with increased breast cancer risk in an African American contemporary cohort of women with benign breast disease

Research article

The isomiR-140-3p-regulated mevalonic acid pathway as a potential target for prevention of triple negative breast cancer

Correction

Correction to: Intracellular hypoxia measured by F-18 fluoromisonidazole positron emission tomography has prognostic impact in patients with estrogen-receptor positive breast (BRCR-D17-00693)

Research article

Assessing brain volume changes in older women with breast cancer receiving adjuvant chemotherapy: a brain magnetic resonance imaging pilot study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits